EVOLVE: A Virtual, Observational, Patient-Centric Prospective Study to Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin to Patients With Pulmonary Arterial Hypertension
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Treprostinil (Primary) ; Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms EVOLVE
- Sponsors United Therapeutics Corporation
Most Recent Events
- 16 Jan 2025 Status changed from active, no longer recruiting to discontinued.
- 15 Dec 2023 Planned End Date changed from 30 Apr 2024 to 31 Dec 2024.
- 15 Dec 2023 Planned primary completion date changed from 28 Feb 2024 to 31 Dec 2024.